GLP-1 & compounded medication availability in Delaware (2026)
Delaware wrote its telehealth rules directly into the state code, and they read like a checklist for doing remote medicine properly: the provider relationship can begin online, but a prescription can never rest on an internet questionnaire alone. Pair that with a pharmacy regulator that licenses out-of-state pharmacies through a dedicated nonresident path, and you get a small state with unusually clear rules. Here is the complete ten-line availability picture for Delaware addresses.
Every line we track, for Delaware addresses
| Product line | Available in Delaware? | Typical delivery | Notes |
|---|---|---|---|
| GLP-1 (compounded semaglutide) | Yes | 8–10 business days | Dispensed by partner pharmacies holding Delaware’s nonresident credential. |
| GLP-1/GIP (compounded tirzepatide) | Yes | 8–10 business days | Identical national pricing per dose, Wilmington to Fenwick Island. |
| NAD+ | Yes | 8–10 business days | Ordered through the standard online evaluation flow. |
| Sermorelin | Yes | 8–10 business days | Shipped by licensed partner pharmacies statewide. |
| Glutathione | No | N/A | Outside the current OrderlyMeds formulary; listed anyway. |
| BPC-157 | Yes | 8–10 business days | Compounded injectable, patient-specific prescription; federal section below. |
| TB-500 | Yes | 8–10 business days | Compounded injectable; the federal facts are set out below. |
| KPV | No | N/A | Not offered in any state, since peptides here are injectable-only and KPV is not. |
| Epitalon | Yes | 8–10 business days | Compounded injectable; its federal record follows below. |
| MOTS-c | Yes | 8–10 business days | Compounded injectable whose federal record differs from its siblings, below. |
Where a line is missing from our formulary, the row says No rather than vanishing. The gap is the information. Delaware facts last reviewed November 16, 2026.
Research peptides in Delaware: BPC-157, TB-500, KPV, Epitalon & MOTS-c
Delaware patients can order four of these five from OrderlyMeds: BPC-157, TB-500, Epitalon and MOTS-c, every one a compounded injectable on a patient-specific prescription. Delaware’s own telehealth code reinforces that condition, since no prescription here may rest on a questionnaire alone. KPV we do not compound in any state; it is not an injectable line. Each peptide’s federal record is stated below in full, available or not, because that record is the substance of the matter.
BPC-157 in Delaware
In the Delaware offering as a compounded injectable, filled on a patient-specific prescription after a real provider evaluation. Federal record below.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
TB-500 in Delaware
Orderable for Delaware addresses as a compounded injectable on a patient-specific prescription. The two federal facts below go with it.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
KPV in Delaware
Not in the OrderlyMeds formulary for Delaware or any state, because our peptide compounding is injectable-only, which excludes KPV.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
Epitalon in Delaware
Ships to Delaware as a compounded injectable under a patient-specific prescription. Its federal evaluation history is next.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
MOTS-c in Delaware
Available for Delaware addresses as a compounded injectable on a patient-specific prescription; its federal record below is its own, not the other four lines’ wording reused.
FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.
What Delaware’s pharmacy regulators say about compounded medications
Two documents define Delaware for a telehealth patient: the pharmacy regulator’s licensing framework, which covers pharmacies both inside and outside the state, and Title 24, Chapter 60 of the Delaware Code, the telehealth chapter, which spells out how a remote provider relationship must be formed before anything is prescribed.
The Delaware Board of Pharmacy licenses pharmacies both in Delaware and elsewhere; an out-of-state pharmacy dispensing into the state does so under the board’s dedicated non-resident pharmacy licensure. Source: Delaware Board of Pharmacy (Division of Professional Regulation).
Under 24 Del. C. ch. 60, a provider-patient relationship may be established through telehealth (§6003), including diagnosis via audio-visual communication — but a prescription may not be issued solely in response to an internet questionnaire, an internet consult, or a telephone consult (§6003(c)). Source: 24 Del. C. ch. 60 — Telehealth and Telemedicine.
No GLP-1-specific or peptide-specific restriction has been published by the Delaware Board of Pharmacy; compounded medications enter the state through the licensure framework above. Source: Delaware Board of Pharmacy.
Delaware’s insistence on a real evaluation before a prescription is the way OrderlyMeds works everywhere: an eligibility check, then an actual provider encounter rather than a bare form, then fulfillment by a pharmacy credentialed for the state, tracked to your door inside the published 8–10 business-day window at the same flat national price.
Delaware availability FAQs
Is compounded semaglutide available in Delaware?
Yes. OrderlyMeds ships compounded semaglutide to Delaware addresses through pharmacies holding the state’s nonresident credential, at the flat national price.
Can my Delaware treatment start entirely online?
Yes. Delaware’s telehealth chapter lets the provider relationship begin remotely, with one firm condition: a prescription can’t be based on an internet questionnaire alone. A real provider evaluation is required, which is the only way OrderlyMeds operates. The cited detail is in the regulator section above.
Which peptides can Delaware patients order?
BPC-157, TB-500, Epitalon and MOTS-c ship as compounded injectables on patient-specific prescriptions. KPV is the standing exception in every state. The sections above state each line’s cited federal record.
How long until a Delaware order arrives?
8–10 business days from signup is the published window; small-state geography sometimes beats it, and tracking is emailed either way.
Keep exploring
Ready when you are
See if you’re eligible
Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.
Check eligibilitySecure. Private. No commitment
